Literature DB >> 16545970

Metabolism of a liver-selective nitric oxide-releasing agent, V-PYRRO/NO, by human microsomal cytochromes P450.

Keiko Inami1, Raymond W Nims, Aloka Srinivasan, Michael L Citro, Joseph E Saavedra, Arthur I Cederbaum, Larry K Keefer.   

Abstract

Endogenously generated nitric oxide (NO) mediates a host of important physiological functions, playing roles in the vascular, immunological, and neurological systems. As a result, exogenous agents that release NO have become important therapeutic interventions and research tools. O(2)-Vinyl 1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate (V-PYRRO/NO) is a prodrug designed with the hypothesis that it might release nitric oxide via epoxidation of the vinyl group by cytochrome P450, followed by enzymatic and/or spontaneous epoxide hydration to release the ultimate NO-donating moiety, 1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate (PYRRO/NO) ion. In this study, we investigated this hypothetical activation mechanism quantitatively for V-PYRRO/NO using cDNA-expressed human cytochrome P450 (CYP)2E1. Incubation with CYP2E1 and an NADPH-regenerating system resulted in a time-dependent decomposition of V-PYRRO/NO, with a turnover rate of 2.0 nmol/min/pmol CYP2E1. Nitrate and nitrite were detected in high yield as metabolites of NO. The predicted organic metabolites pyrrolidine and glycolaldehyde were also detected in near-quantitative yields. The enzymatic decomposition of V-PYRRO/NO was also catalyzed, albeit at lower rates, by CYP2A6 and CYP2B6. We conclude that the initial step in the metabolism of V-PYRRO/NO to NO in the liver is catalyzed efficiently but not exclusively by the alcohol-inducible form of cytochrome P450 (CYP2E1). The results confirm the proposed activation mechanism involving enzymatic oxidation of the vinyl group in V-PYRRO/NO followed by epoxide hydration and hydrolytic decomposition of the resulting PYRRO/NO ion to generate nitric oxide.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16545970     DOI: 10.1016/j.niox.2006.01.003

Source DB:  PubMed          Journal:  Nitric Oxide        ISSN: 1089-8603            Impact factor:   4.427


  6 in total

1.  The Nitric Oxide Prodrug V-PROLI/NO Inhibits Cellular Uptake of Proline.

Authors:  Sam Y Hong; Gregory L Borchert; Anna E Maciag; Rahul S Nandurdikar; Joseph E Saavedra; Larry K Keefer; James M Phang; Harinath Chakrapani
Journal:  ACS Med Chem Lett       Date:  2010-11-11       Impact factor: 4.345

2.  Nitric oxide donor, V-PROLI/NO, provides protection against arsenical induced toxicity in rat liver cells: requirement for Cyp1a1.

Authors:  Wei Qu; Lida Cheng; Anna L Dill; Joseph E Saavedra; Sam Y Hong; Larry K Keefer; Michael P Waalkes
Journal:  Chem Biol Interact       Date:  2011-05-20       Impact factor: 5.192

3.  Iron regulatory protein 1 outcompetes iron regulatory protein 2 in regulating cellular iron homeostasis in response to nitric oxide.

Authors:  Agnieszka Styś; Bruno Galy; Rafal R Starzyński; Ewa Smuda; Jean-Claude Drapier; Pawel Lipiński; Cécile Bouton
Journal:  J Biol Chem       Date:  2011-05-12       Impact factor: 5.157

4.  Novel protection-deprotection strategies in diazeniumdiolate chemistry: synthesis of V-IPA/NO.

Authors:  Rahul S Nandurdikar; Larry K Keefer; Joseph E Saavedra
Journal:  Chem Commun (Camb)       Date:  2011-05-10       Impact factor: 6.222

5.  V-PROLI/NO, a nitric oxide donor prodrug, protects liver cells from arsenic-induced toxicity.

Authors:  Wei Qu; Jie Liu; Anna L Dill; Joseph E Saavedra; Larry K Keefer; Michael P Waalkes
Journal:  Cancer Sci       Date:  2008-12-15       Impact factor: 6.716

6.  Ruthenium red protects HepG2 cells overexpressing CYP2E1 against acetaminophen cytotoxicity.

Authors:  Adam Holownia; Jakub Jablonski; Anna Skiepko; Robert Mroz; Edyta Sitko; Jan J Braszko
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-08-27       Impact factor: 3.000

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.